Infliximab Maintenance Therapy for Fistulizing Crohn's Disease

20042,202 citationsJournal Articlebronze Open Access

Authors

Bruce E. Sands · Harvard University

Frank Anderson · Vancouver General Hospital

Çharles N. Bernstein · Health Sciences Centre

William Y. Chey

Brian G. Feagan · Western University

Richard N. Fedorak · University of Alberta

Michael A. Kamm · St. Mark's Hospital

Abstract

Patients with fistulizing Crohn's disease who have a response to induction therapy with infliximab have an increased likelihood of a sustained response over a 54-week period if infliximab treatment is continued every 8 weeks.

Topics & Keywords

Inflammatory Bowel Disease Microscopic Colitis Autoimmune and Inflammatory Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 350, Issue 9, pp. 876-885

DOI: 10.1056/nejmoa030815

Field-Weighted Citation Impact: 71.07